戴維醫療(300314.SZ):子公司維爾凱迪吻合器產品完成延續註冊
格隆匯7月26日丨戴維醫療(300314.SZ)公佈,公司全資子公司維爾凱迪於近日取得由浙江省藥品監督管理局頒發的1項《醫療器械註冊證》。產品名稱:一次性使用腔鏡切割吻合器及組件;註冊分類:Ⅱ類;用途:產品用於腔鏡下消化道重建及臟器切除手術中的殘端或切口的閉合。
公司表示,該次延續註冊的完成,使得維爾凱迪可以繼續生產和銷售吻合器相關產品,對公司未來經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.